Date: 2015-03-03
Type of information: Nomination
Compound:
Company: Atara Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Kidney diseases - Renal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 3, 2015, Atara Biotherapeutics, a biopharmaceutical company focused on innovative therapies for patients with debilitating diseases, announced that it has hired David A. Carmel as Head of Immunotherapy. Mr. Carmel will lead Atara\'s efforts in its collaboration with Memorial Sloan-Kettering Cancer Center (MSK) to develop and commercialize allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. The collaboration will initially focus on development and regulatory activities for the three clinical stage targeted T-cell programs that Atara believes offer the most rapid path to marketing approvals. Atara and MSK also intend to expand research and development through sponsored research funded by Atara. Atara recently announced that MSK received breakthrough therapy designation from the FDA for its cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV - CTL) in the treatment of patients with rituxamab-refractory, EBV-associated lymphoproliferative disease. Prior to joining Atara, Mr. Carmel was a co-founder and principal of Carmel Asset Management, an investment partnership where he was responsible for life science investments. Previously, he led corporate development for StemCyte, Inc., a cell therapeutics company with operations in the U.S., Taiwan, and India. He worked on the California Stem Cell Research and Cures Initiative, a ballot initiative approved by voters in 2004 that provided $3 billion to fund stem cell research. Earlier, he worked in U.S. Planning and Business Development at Pfizer, Inc., and at Independence Technology, a division of the Johnson & Johnson Corporation. Mr. Carmel served as the White House Fellow for the Secretary of the Treasury from 2002 to 2003. Mr. Carmel is a founding board member of the New York Stem Cell Foundation, a member of the New York State Spinal Cord Injury Research Board, a co-founder of New Yorkers for Cures and a Henry Crown Fellow of the Aspen Institute. He earned a bachelor\'s degree, magna cum laude, from Harvard College and an MBA with a certificate in health care from the Stanford Graduate School of Business.
Financial terms:
Latest news:
